LENZ Therapeutics (LENZ) has received a new Buy rating, initiated by TD Cowen analyst, Stacy Ku.
Stacy Ku has given his Buy rating due to a combination of factors surrounding LENZ Therapeutics’ promising presbyopia treatment, LNZ100. The drug has shown best-in-class efficacy and a clean safety profile in its Phase III trials, which has led to high consumer satisfaction expectations. With FDA approval anticipated by August 2025, LNZ100 is poised to address a significant unmet need in the presbyopia market, potentially capturing a substantial share of the market.
Optometrist feedback has been overwhelmingly positive, highlighting the drug’s differentiated pupil effect and lack of adverse events commonly associated with other treatments. This positive reception, coupled with the expectation of high patient demand and favorable pricing, suggests a strong commercial opportunity for LNZ100. These factors contribute to Stacy Ku’s confidence in the stock’s potential, supporting the Buy rating and a price target of $60.